- Home
- INCY vs LBRDK Comparison
INCY vs LBRDK Comparison
Compare INCY & LBRDK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- LBRDK
- Stock Information
- Founded
- INCY 1991
- LBRDK 2014
- Country
- INCY United States
- LBRDK United States
- Employees
- INCY N/A
- LBRDK N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- LBRDK Cable & Other Pay Television Services
- Sector
- INCY Health Care
- LBRDK Telecommunications
- Exchange
- INCY Nasdaq
- LBRDK Nasdaq
- Market Cap
- INCY 13.0B
- LBRDK 13.0B
- IPO Year
- INCY 1993
- LBRDK N/A
- Fundamental
- Price
- INCY $70.20
- LBRDK $70.22
- Analyst Decision
- INCY Hold
- LBRDK Strong Buy
- Analyst Count
- INCY 20
- LBRDK 1
- Target Price
- INCY $72.75
- LBRDK $91.00
- AVG Volume (30 Days)
- INCY 1.5M
- LBRDK 2.1M
- Earning Date
- INCY 07-29-2025
- LBRDK 08-07-2025
- Dividend Yield
- INCY N/A
- LBRDK N/A
- EPS Growth
- INCY N/A
- LBRDK 6.21
- EPS
- INCY 0.10
- LBRDK 6.26
- Revenue
- INCY $4,413,226,000.00
- LBRDK $1,037,000,000.00
- Revenue This Year
- INCY $13.48
- LBRDK $6.00
- Revenue Next Year
- INCY $10.37
- LBRDK $2.32
- P/E Ratio
- INCY $723.63
- LBRDK $11.22
- Revenue Growth
- INCY 17.13
- LBRDK 5.82
- 52 Week Low
- INCY $53.56
- LBRDK $52.15
- 52 Week High
- INCY $83.95
- LBRDK $97.38
- Technical
- Relative Strength Index (RSI)
- INCY 55.91
- LBRDK 24.37
- Support Level
- INCY $67.17
- LBRDK $86.47
- Resistance Level
- INCY $71.29
- LBRDK $91.79
- Average True Range (ATR)
- INCY 1.51
- LBRDK 2.62
- MACD
- INCY 0.06
- LBRDK -1.47
- Stochastic Oscillator
- INCY 74.23
- LBRDK 2.19
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About LBRDK Liberty Broadband Corporation Class C
Liberty Broadband Corp serves in the telecommunications industry in the United States. It provides cable services to both residential andsommercial businesses through its fiber, hybrid fiber, and coaxial cable infrastructure. The services provided by the company are residential services which include video services, internet services, voice services, and mobile services, commercial services which include small, and medium business and enterprise solutions, advertising services, and other services. The reportable segments of the company are GCI Holdings, Charter. The firm derives the majority of its revenue from GCI Holdings.